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STUDY OBJECTIVES To identify baseline predictors of worsening renal function (WRF) in an acute de-
compensated heart failure (ADHF) patient population receiving continuous infusion loop diuretics
DESIGN Retrospective observational analysis.
SETTING Academic tertiary medical center.
PATIENTS A total of 177 patients with ADHF receiving continuous infusion loop diuretics from January
2006 through June 2009.
MEASUREMENTS AND MAIN RESULTS The mean patient age was 61 years, 63% were male, ~45% were classified
as New York Heart Association functional class III, and the median length of loop diuretic infusion was
4 days. Forty-eight patients (27%) developed WRF, and 34 patients (19%) died during hospitalization.
Cox regression time-to-event analysis was used to determine the time to WRF based on different demo-
graphic and clinical variables. Baseline serum albumin 3 g/dl or less was the only significant predictor of
WRF (hazard ratio [HR] 2.87, 95% confidence interval [CI] 1.60–5.16, p=0.0004), which remained signif-
icant despite adjustments for other covariates.
CONCLUSION Serum albumin 3 g/dl or less is a practical baseline characteristic associated with the
development of WRF in patients with ADHF receiving continuous infusion loop diuretics.
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Worsening renal function (WRF) occurs in
30–50% of patients hospitalized for decompen-
sated heart failure1–3 and is as prevalent as WRF
in patients with circulatory shock, hypotension,
cardiac arrest, sepsis, or acute coronary syn-
drome.1, 2 WRF in patients with heart failure
(HF) is associated with increased mortality,1, 2, 4
increased length of hospital stay,1, 2 higher in-
hospital cost,2 and re-hospitalization.1, 2, 4 The
development of WRF in patients with HF limits
the use of survival-impacting therapies such as
angiotensin-converting enzyme (ACE) inhibitors
or spironolactone. Renal dysfunction activates
the renin-angiotensin-aldosterone system to pre-
serve renal perfusion and circulatory homeostasis,
both of which can contribute to the patho-
physiology of HF.5
Serum creatinine,1, 2 pulmonary edema,1
female gender, rales, tachycardia (pulse higher
than > 100 bpm), systolic blood pressure higher
than 200 mm Hg,2 chronic kidney disease, loop
diuretic dose upon hospital admission, New
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York Heart Association (NYHA) functional class,
and left ventricular ejection fraction (LVEF) less
than 30%3 are independent predictors of WRF
in patients with HF. In a retrospective analysis
of the Coordinating Study Evaluating Outcome
of Advising and Counseling in Heart Failure
(COACH) study (n = 1023) age, type 2 diabetes,
and anemia were independent predictors of
WRF over 18 months (including in- and out-of-
hospital WRF).4 In the COACH study, WRF sig-
nificantly increased the number of unfavorable
days (i.e., days in the hospital or dead). Because
WRF may contribute to increased hospital stay
as well as increased morbidity, it is important to
understand predictors of WRF.1, 2, 4 To our
knowledge, no studies have evaluated baseline
predictors of WRF associated with continuous
infusion of loop diuretics. Patients treated with
continuous infusion loop diuretics are a unique
patient population. Typically these patients are
diuretic resistant or unable to tolerate the hypo-
tension secondary to fluid shifts associated with
loop diuretics infused on an intermittent sche-
dule. Continuous infusion of loop diuretics
increases the risk of WRF and can increase the
length of hospital stay.1, 2 Furosemide is the
loop diuretic most often used in continuous-
infusion regimens. Use of bumetanide is less
common. Therefore, the aim of this study was to
identify baseline predictors of WRF in patients
with acute decompensated heart failure (ADHF)
receiving continuous infusions of the loop
diuretics furosemide and bumetanide.
Methods
Design Overview
We conducted a retrospective review of patient
records to determine predictors of WRF in patients
with ADHF receiving continuous infusions of loop
diuretics. The study was approved by the Univer-
sity of Michigan institutional review board.
Patient Population
All patients admitted to the University of
Michigan Health System with ADHF, receiving
continuous infusion of loop diuretics from Janu-
ary 2006 through June 2009, were included.
Exclusion criteria were incomplete medical
records, less than 24 hours of loop diuretic infu-
sion treatment, concurrent nephrotoxic agents
(aminoglycosides, tacrolimus, cyclosporine, and
sirolimus), dialysis, prior infusions of loop
diuretics at an outside hospital, and age younger
than 18 years. The most common reason for
exclusion was loop diuretic infusion treatment
for less than 24 hours. For patients with multi-
ple admissions during the study, only index
hospitalization was included in the analysis.
Outcome Measures
The primary goal of this study was to identify
baseline predictors of time to WRF in patients
with ADHF who were receiving continuous infu-
sion loop diuretics. Worsening renal function
was defined as any increase in baseline serum
creatinine of 0.3 mg/dl or more during continu-
ous infusion of loop diuretic. This rise in serum
creatinine is consistent among other studies of
WRF.6, 7 In-hospital mortality, defined as in-
hospital death, was also collected.
Statistical Analysis
Cox regression was performed as a time-to-
event analysis to determine the time to WRF
based on different baseline variables. Clinical
characteristics were then associated with time to
WRF. Baseline variables were dichotomized
when data for continuous variables were not
normally distributed. Patients were evaluated
until discharge or in-hospital death. Each vari-
able was tested univariately and then retested
after adjustments for other possible cofounders
in the Cox model. Variables with p<0.1 in the
univariate Cox regression analysis were used in
the multivariable Cox model.
The following baseline clinical characteristics
were considered in the analysis (Table 1): age,
gender, weight, height, specific loop diuretic
infused, primary etiology of HF (ischemic versus
nonischemic, systolic versus diastolic), NYHA
functional class, LVEF (less than 40%), history
of diabetes mellitus, hypertension, or peripheral
vascular disease, atrial fibrillation, chronic kid-
ney disease, automatic implantable cardioverter-
defibrillator, dose of preinfusion loop diuretic,
systolic blood pressure, serum creatinine, serum
sodium, aspartate amino transferase (more than
three times the upper limit of normal [ULN]),
alanine amino transferase (more than three times
the ULN), alkaline phosphatase (higher than our
laboratory ULN), serum albumin and total pro-
tein (lower than our laboratory cut-off for nor-
mal), and B-type natriuretic peptide (BNP)
(divided into quartiles). For purposes of this
study, baseline was defined as the start of loop
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Table 1. Baseline Characteristics
Variables Overall Cohort (n=177) No WRF (n=129) WRF (n=48) HR (95% CI) p Value
Age (yrs) 60.8  15.2 60.4  15.1 62.1  15.4 1.01 (0.99–1.01) 0.50
Weight (kg) 94.3  28.8 95.7  30.5 90.7  23.5 1.00 (0.99–1.01) 0.37
Height (in.) 67.6  4.4 67.4  4.5 68.1  4.7 1.03 (0.97–1.1) 0.36
Male 111 (62.7) 77 (59.7) 34 (70.8) 0.57 (0.30–1.07 0.08
White 127 (71.8) 92 (71.2) 35 (72.9) 0.83 (0.43–1.07 0.57
Loop diuretic infusion
Bumetanide 137 (77.4) 96 (74.2) 41 (85.4) 1.6 (0.72–3.57) 0.25
Furosemide 40 (22.6) 33 (25.6) 7 (14.6)
Comorbidities
Diabetes 81 (45.8) 59 (45.7) 22 (45.8) 0.98 (0.55–1.75) 0.95
Hypertension 91 (51.4) 56 (51.1) 25 (52.1) 1.14 (0.64–2.02) 0.65
Atrial fibrillation 83 (46.9) 62 (48.1) 21 (43.8) 0.73 (0.41–1.31) 0.29
ICD present 89 (50.3) 69 (53.5) 20 (41.7) 0.72 (0.40–1.28) 0.26
CKD 100 (56.5) 75 (58.1) 25 (52.1) 0.69 (0.39–1.23) 0.21
PVD 18 (10.2) 10 (7.8) 8 (16.7) 2.02 (0.94–4.36) 0.07
Heart failure characteristics
ICM 84 (51.9) 58 (48.7) 26 (60.5) 1.44 (0.81–2.58) 0.22
NICM 78 (48.1) 61 (51.3) 17 (39.5)
Systolic dysfunction 125 (71.2) 95 (79.9) 30 (69.8) 1.62 (0.81–3.24) 0.17
Diastolic dysfunction 34 (21.0) 23 (19.3) 11 (25.6)
PHTN with RHF 40 (22.6) 29 (22.5) 11 (22.9) 0.92 (0.47–1.81) 0.81
Ejection fraction < 40% 118 (67.1) 87 (67.8) 31 (64.6) 1.15 (0.63–2.10) 0.64
NYHA class
II 41 (23.2) 28 (21.7) 13 (27.1) 1.1 (0.53–2.27) 0.80b
III 79 (44.6) 62 (48.1) 17 (35.4) 0.74 (0.38–1.45) 0.38c
IV 57 (32.2) 39 (30.2) 18 (37.5) – –
SBP (mm Hg) 109.9  20.7 110.1  20.8 109.6  20.5 1.00 (0.99–1.01) 0.99
Baseline laboratory values
Serum sodium 135.7  4.9 135.4  5.0 136.6  4.5 1.04 (0.97–1.10) 0.25
Serum creatinine 1.8  0.8 1.9  0.9 1.6  0.7 0.72 (0.49–1.06) 0.1
AST > 90 IU/L 89 (51.2)
(n=173)a
63 (49.6)
(n=127)a
26 (55.3)
(n=47)a
1.47 (0.82–2.64) 0.20
ALT > 105 IU/L 63 (36.2)
(n=173)a
43 (33.9)
(n=127)a
20 (42.6)
(n=47)a
1.33 (0.74–2.40) 0.34
Alk Phos > 130 IU/L 56 (32.2)
(n=173)a
40 (31.5)
(n=127)a
16 (34.0)
(n=47)a
0.97 (0.52–1.79) 0.92
Serum albumin ≤ 3 mg/dl 34 (19.8)
(n=172)a
15 (12.0)
(n=125)a
19 (40.4)
(n=47)a
2.86 (1.59–5.13 0.0004
Total protein < 6 g/dl 63 (38.0)
(n=166)a
40 (33.0)
(n=121)a
23 (51.1)
(n=45)a
1.71 (0.95–3.10) 0.07
BNP (pg/ml) (n=164)a (n=120)a (n=44)a
< 470 41 (25.0) 28 (23.3) 13 (29.6) 1.25 (0.55–2.84) 0.60d
470–952 40 (24.4) 30 (25.0) 10 (22.73) 0.99 (0.41–2.38) 0.98e
953–1899 24 (25.6) 31 (25.8) 11 (25.0) 1.03 (0.44–2.42) 0.95f
> 1899 41 (25.0) 31 (25.8) 10 (22.7) – –
Baseline medications
ACEI or ARB 47 (26.6) 39 (30.2) 8 (16.7) 0.64 (0.30–1.39) 0.26
b-Blocker 77 (43.5) 61 (47.3) 16 (33.3) 0.59 (0.32–1.07) 0.08
Digoxin 53 (30.0) 41 (31.8) 12 (25.0) 0.82 (0.43–1.58) 0.56
Spironolactone 46 (26.0) 36 (27.9) 10 (20.8) 0.69 (0.34–38) 0.29
Inotropes/vasopressors 59 (33.3) 41 (31.2) 18 (37.5) 1.21 (0.67–2.20) 0.53
Thiazide diuretic 41 (23.2) 27 (20.9) 14 (29.2) 1.14 (0.60–2.14) 0.69
Values are represented as means  SD or n (%).
The p values were calculated by the Student t test or v2 or Fisher exact test.
WRF = worsening renal function; HR = hazard ratio; CI = confidence interval; ICD = implantable cardioverter-defibrillator; CKD = medical
record diagnosis of chronic kidney disease; PVD = peripheral vascular disease; ICM = ischemic cardiomyopathy; NICM = nonischemic car-
diomyopathy; PHTN = pulmonary hypertension; RHF = right heart failure; NYHA = New York Heart Association; SBP = systolic blood pres-
sure; AST = aspartate amino transferase; ALT = alanine amino transferase; Alk Phos = alkaline phosphatase; BNP = b-type natriuretic
peptide; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.
aLaboratory values not available for all patients.
bNYHA class II vs IV.
cNHYA class III vs IV.
d< 470 pg/ml vs > 1899 pg/ml.
e470–952 pg/ml vs > 1899 pg/ml.
f953–1899 pg/ml vs > 1899 pg/ml.
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diuretic infusion during hospitalization. The fol-
lowing medications were adjusted for as dichot-
omous variables, indicating the use or nonuse of
the medication at the time of loop infusion initi-
ation: digoxin, b-blockers, ACE inhibitors,
angiotensin II receptor blockers, thiazide diuret-
ics, and spironolactone. Regression analysis also
adjusted for intravenous inotropic and vasopres-
sor therapy. Bumetanide doses were converted
to furosemide equivalents (i.e., 1 mg intravenous
bumetanide = 40 mg intravenous furosemide).
All statistical analyses were performed using SAS
software v.9.2 (SAS Institute, Cary, NC, USA).
Results
Of the 384 records reviewed, 177 patients met
the inclusion and exclusion criteria. Overall the
population was predominantly male (63%) and
white (72%), with a mean age of 61 plus or
minus 15 years. Approximately 50% of the
patients had diabetes, chronic kidney disease, or
atrial fibrillation, and the mean LVEF was 31%.
Patients received continuous infusions of loop
diuretic for a median of 4 days (range 1–12 days).
Bumetanide was the most common agent used
(77%). There were no significant differences in
patient demographics, HF characteristics, NYHA
functional class, baseline blood pressure, or
baseline medication use. Most patients (44.6%)
were categorized as NYHA functional class III,
and ~30% were receiving intravenous inotropic
or vasopressor agents. Table 1 presents the base-
line demographic characteristics and clinical fea-
tures of patients who developed WRF versus
those who did not develop WRF.
Time to Worsening Renal Function
Forty-eight patients (27%) experienced WRF
during continuous infusion loop diuretic. The
median time to WRF was 2 days. Variables with
p<0.1 in the univariate Cox regression analysis
that were used in the multivariable Cox model
were peripheral vascular disease, baseline total
protein, baseline serum creatinine, baseline b-
blocker use, and baseline serum albumin.
Univariate analysis demonstrated that baseline
albumin (3 g/dl or less, hazard ratio [HR] 2.87,
95% confidence interval [CI] 1.60–5.16,
p=0.0004) was the only characteristic that pre-
dicted WRF (Figure 1). Serum albumin 3 g/dl or
less remained a significant predictor of WRF
during multivariate analysis. The furosemide-
equivalent infusion dose on day 1 was not differ-
ent between the two groups (more than 685 mg
in furosemide equivalents, 48% of patients with-
out WRF and 54% with WRF, HR 0.86, 95% CI
0.64–1.19, p=0.50). Day 1 urine output for
patients who developed WRF during hospitaliza-
tion (825  1384 ml) was lower than in
patients who did not develop WRF
(1512  1824 ml, p=0.0089).
In-Hospital Mortality
Patients with WRF were more likely to die
during the index hospitalization than were
patients who did not develop WRF (35.4% ver-
sus 13.2%, respectively; odds ratio 3.61, 95% CI
1.65–7.89, p=0.0008). An association was also
shown with albumin 3 g/dl or less and in-hospi-
tal mortality (35.3% WRF versus 15.9% no
WRF; odds ratio 2.86, 95% CI 1.24–6.65,
p=0.011).
Discussion
The purpose of this study was to identify
patient characteristics that could enable clini-
cians to identify risk of renal dysfunction during
continuous infusion of loop diuretics. The char-
acteristic that predicted WRF was baseline
serum albumin level of 3 g/dl or less, which we
view as a clinically low value. WRF was not
associated with typical predictors for WRF
including baseline serum creatinine, the amount
of diuretic received during the study period, or
net urine output over the first 24 hours. Wors-
ening renal function was also associated with
increased rates of in-hospital mortality, which
were 2-fold higher in patients with low serum
albumin levels.
Figure 1. Event-free time to worsening renal function
probability curves with data represented as a Cox
regression model according to baseline albumin > 3 g/dl
versus ≤ 3 g/dl. The p values <0.05 are considered
significant. CI = confidence interval; HR = hazard ratio.
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The patients in this study represent a real-
world acutely ill population seen in a tertiary
care academic medical center with a heart trans-
plant/ventricular assist device program. These
patients tended to have severe HF with low
serum sodium, elevated serum creatinine, inotro-
pic therapy, elevated BNP (more than 50% of
patients had BNP higher than 1000 pg/ml), and
high rates of in-hospital mortality. Patients who
developed WRF, had significantly lower serum
albumin (albumin 3 mg/dl or less in 40% of
patients in the WRF group versus 12% of
patients in the group that did not develop WRF;
p=0.0004). Although not significant in the mul-
tivariable model, patients with WRF had lower
body weight, lower serum creatinine, and lower
total protein (total protein less than 6 g/dl in
51% of the WRF group versus 33% in the group
that did not develop WRF; p=0.07) (Table 1).
Interestingly, in a post-hoc analysis of the Evalu-
ation Study of Congestive Heart Failure and Pul-
monary Artery Catheterization Effectiveness
(ESCAPE) trial, patients who developed WRF8
had similar baseline features as the patients in
the current study (significantly lower serum
albumin, total protein, and serum creatinine lev-
els; p<0.011). In the ESCAPE trial, intravascular
volume contraction determined by hemoconcen-
tration (based on changes in hematocrit, serum
albumin, total protein) induced by aggressive in-
hospital diuresis was associated with WRF. The
net urine output was significantly greater and
diuretic dose was significantly higher in the
patients with hemoconcentration.8 In contrast,
we found net urine output was significantly
lower in patients with WRF than in patients
who did not develop WRF. Our findings suggest
that low serum albumin is associated with WRF
and not related to aggressive diuresis measured
by net urine output and diuretic dose.
The reason why patients with low serum albu-
min may be more likely to develop WRF is not
certain, but it may relate to the degree of intra-
vascular volume depletion. When fluid is lost
from the intravascular compartment via diuretic-
induced diuresis, it needs to be replaced by the
fluid in the extravascular space (i.e., peripheral
edema). If fluid is not replaced rapidly enough,
intravascular volume contraction may occur and
contribute to WRF.8, 9 Physiologically, a factor
that contributes to the movement of fluid
between the extravascular and intravascular
spaces is oncotic pressure. Theoretically, patients
with lower serum albumin (and overall total
protein) may be at higher risk for developing
WRF due to lower intravascular oncotic pressure
(and associated slower refill rates of the intravas-
cular volume) as compared with patients with
normal serum albumin (and higher oncotic
pressure).9–11 Similar to the ESCAPE study, we
found that patients who developed WRF had
lower serum albumin and total protein (total
protein not statistically significant in our results
for unclear reasons) at baseline.
Another consideration why patients with low
serum albumin levels may be at risk for devel-
oping WRF is that low serum albumin levels
may be a marker for a more “sick” patient pop-
ulation as alluded to in the ESCAPE trial.8 In
fact, studies in patients with HF have shown
that hypoalbuminemia is a predictor of poor
outcomes including mortality.12, 13 Our mortal-
ity data reflect these findings. Hypoalbuminemia
may also represent a set of patients who are
highly congested. It has been suggested that
patients with elevated filling pressures or
patients who are discharged while still con-
gested may have poorer outcomes and may con-
tribute to HF progression.8, 14, 15 A recent study
showed that patients discharged with persistent
congestion had a higher risk of death or acute
HF readmission.14 These findings included
patients with and without WRF. If low serum
albumin does represent patients that are highly
congested, these patients may be a high-risk
population for poor outcomes including devel-
oping WRF.
An important aspect to consider from our
study is the finding that both groups received a
similar initial diuretic dose during the hospital-
ization. These are important findings because
previous studies have associated WRF with
either diuretic dose or diuretic response (i.e.,
excessive diuresis).3, 8 Because both groups in
our study had a similar diuretic course, our
findings that baseline low serum albumin pre-
dicted WRF becomes more valuable to the clini-
cian in assessing risk of WRF in patients with
ADHF. How to prevent WRF in high-risk
patients is not known. It appears that the degree
of diuresis or the modes of administration are
not factors in developing WRF in patients with
low serum albumin levels. It is not known if
alternative methods for diuresis may help pre-
vent in-hospital WRF. For example, ultrafiltra-
tion enables a more controlled diuresis and may
theoretically be of benefit.16 Whether or not
ultrafiltration is associated with less neurohor-
monal activation than loop diuretic therapy is
not certain. Another option may be vasopressin
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antagonist-induced diuresis, which may allow
for very low doses of loop diuretics. The acute
use of both vasopressin antagonists and loop
diuretics appears not to worsen renal function in
HF patients.17 However, it is not known if the
plasma refill rate would be any different between
the use of vasopressin antagonists and diuretics
versus diuretics alone. Although low serum albu-
min and protein levels in our study were likely
due to excess fluid volume, evaluation for
malnutrition and cachexia may be another
consideration. Nutritional consultation in these
patients may be of benefit over the long term.
Finally, it is not known if albumin infusions would
prevent worsening renal function in this patient
population.
A limitation of the study is that we do not
know the exact mechanism(s) for WRF during
diuresis in patients with low serum albumin. As
such, we do not know the best approach to
preventing WRF. However, this study does
provide data to target a specific type of patient
for evaluation and testing. Obvious concerns
with the study also include the relatively small
number of patients, the retrospective design, and
lack of more details regarding inpatient clinical
course that may provide more information about
potentially confounding clinical features. The
patients in this study were seriously ill, both
acutely in terms of decompensated HF, but also
chronically. We do not know if our findings
would be the same in a less critically ill popula-
tion.
Overall, this study found that baseline serum
albumin concentration of 3 mg/dl or less pre-
dicted WRF in patients with ADHF who received
continuous infusion loop diuretics. Patients
presenting with hypoalbuminemia and ADHF
may represent an at-risk population. Further
investigation regarding this subset of patients is
warranted.
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